C-PSJKBlue Rock Therapeutics (owned by Bayer)
cell therapy, cellular medicine
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PSJK
C-PSJKC-PSJKcell therapy, cellular medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Ophthalmics Collaboration and Licensing Agreements Benchmark Report 2026: Structured Analysis of 374 Deals - Upfronts, Milestones, and Royalty Structures Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 1h 32m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 1h 32m FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3204 +0.0006 +0.05% GBP/EUR 1.1600 +0.0003 +0.03% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,029.60 -18.00
As filed with the U.S. Securities and Exchange Commission on November 6, 2025. Registration No. 333-            UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________________________ Bluerock Acquisition Corp. (Exact name of registrant as specified in its charter) ________________________________________ Cayman Islands   6770   N/A (State or other jurisdiction of incorporation or orga … ic market for our units, Class A ordinary shares or warrants. We intend to apply to have our units listed on The Nasdaq Global Market, or Nasdaq, under the symbol “BLRKU,” on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq. We expect the Class A ordinary shares and warrants comprising the units to begin separate trading on the 52 nd  day following the date of this prospect … 2; Risks Relating to our Sponsor and Management Team — The grant of registration rights to our sponsor, the underwriter and other holders of our private placement warrants may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our Class A ordinary shares .” Members of our management team will directly or indirectly own founder shares and/or private … ll any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any units, 6 Table of Contents warrants, ordinary shares or any other securities convertible into, or exercisable or exchangeable for, any units, ordinary shares, founder shares, or warrants, subject to certain exceptions. The representative in its discretion may release any of the sec … off from BRG in 2022, as well as Chairman of Bluerock Total Income+ Real Estate Fund and Bluerock High Income Institutional Credit Fund. Mr. Kamfar received an M.B.A. degree with distinction in Finance in 1988 from The Wharton School of the University of Pennsylvania and a B.S. degree with distinction in Finance in 1985 from the University o
BlueRock Therapeutics | Institution outputs | Nature Index Skip to main content Advertisement Search Main Navigation Home News News home News Comment Data insights Dataviz Careers Q+A Archive Current Index Institution rankings Institution benchmarking Institution collaboration Country/territory rankings Country/territory benchmarking Country/territory collaboration Data visualizations Articles Research highlights Topics Topic explorer Nature Index topics Leading institutions by topic Leading countries/territories by topic Research leaders Research leaders home 2026 Research Leaders 2025 Resear … environmental sciences — Physical sciences Social sciences Nature & Science Apply Count: 1 Share: 0.29 Article ‘Count’ and ‘Share’ for BlueRock Therapeutics based on listed parameters only. The articles listed below published by authors from BlueRock Therapeutics, organized by journal and article, represent the research output in Count and Share according to the parameters selected above. Journal Count Share Nature 1 0.29 Numerical information only (in the tables above) i
BlueRock Digital Become Scoro’s First Co-Sell Partner | Scoro BlueRock Digital Become Scoro’s First Co-Sell Partner Use cases Product Resources Pricing Use cases Product Resources Pricing Book a demo 👋 Try for free By industries Consultancy Business, Legal, Accounting, Environmental, etc. Agency Creative, Advertising, Marketing, Digital, PR, etc. Architecture Architecture, Design, Planning, Drafting, etc. Engineering & Construction Engineering, Construction, Infrastructure, etc. Software Dev Software Development, Product Engineering, SaaS, etc. IT Services IT Services, Technology Co … -Sell Partner By Team Scoro Powering Professional Services --> Share Scoro, the award-winning professional services automation (PSA) software for collaborative teams, is ramping up its partner channel to meet increased global demand. Headquartered in the UK, with offices in North America and the Baltics, Scoro’s software helps thousands of agencies, consultancies and professional service firms in 60+ countries work more efficiently. Australia is one of those countries that ha
Wolfram Carius - Director at BlueRock Therapeutics | The Org Platform Enrich Pricing Log in Sign up BlueRock Therapeutics Wolfram Carius Unverified WC Wolfram Carius Director Contact Wolfram Carius is Executive Vice President and Head of Cell and Gene Therapy at Bayer’s Pharmaceutical Division. He was appointed to his current role in October of 2020. Wolfram has also served as Executive Vice President of Pharmaceuticals Product Supply at Bayer. Prior to joining the company, Wolfram was a Senior Vice President at Sanofi, where he was accountable for the technical development and manufacturing
BlueRock Therapeutics | Institution outputs | Nature Index Skip to main content Advertisement Search Main Navigation Home News News home News Comment Data insights Dataviz Careers Q+A Archive Current Index Institution rankings Institution benchmarking Institution collaboration Country/territory rankings Country/territory benchmarking Country/territory collaboration Data visualizations Articles Research highlights Topics Topic explorer Nature Index topics Leading institutions by topic Leading countries/territories by topic Research leaders Research leaders home 2026 Research Leaders 2025 Resear … environmental sciences — Physical sciences Social sciences Nature & Science Apply Count: 1 Share: 0.29 Article ‘Count’ and ‘Share’ for BlueRock Therapeutics based on listed parameters only. The articles listed below published by authors from BlueRock Therapeutics, organized by journal and article, represent the research output in Count and Share according to the parameters selected above. Journal Count Share Nature 1 0.29 Numerical information only (in the tables above) i
BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRock The … ttenberg will oversee BlueRock’s research and discovery efforts, focused on the application and expansion of BlueRock’s cell+gene platform to the creation of engineered cellular medicines. “We are thrilled to have Seth join our team. He brings deep domain expertise in cell therapy and a track record of building and leading high-performance teams in both large pharma and start-up biotech companies,” said Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics. “He is a … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
2026 National Biotechnology Conference Skip to main content Toggle navigation Search Home Icon Legend This session is not in your schedule. This session is in your schedule. Click again to remove it. Favorite Facebook Tweet Print Amit Rakhit, MD, MBA (he/him/his) Chief Medical Officer BlueRock Therapeutics Key Biscayne, Florida Amit Rakhit, MD, MBA is the Chief MEdical Officer at BlueRock Therapeutcs. He is an accomplished pharmaceutical and biotechnology executive with extensive experience leading the development of innovative medicines across oncology, neurology, rare diseases, and cardiovas … re he led international medical teams across 27 countries. Dr. Rakhit completed fellowship training in Pediatric Cardiology at Boston Children's Hospital, earned his MD from Tufts University, a BA from University of California, Berkeley, and dual MBAs from Columbia Business School and London Business School. Disclosure information not submitted. Presentation(s): Executive Track: Guiding Good Science to Patients Through Evolving Markets and an Uncertain Regulatory Environment
BlueRock Therapeutics - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization BlueRock Therapeutics bluerocktx.com Company Details Description BlueRock Therapeutics is a biotech company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platfor … een Columbia Business School and London Business School. He completed a Harvard fellowship training in Pediatric Cardiology at Boston Children’s Hospital. Read More Natasha Rathee Senior Vice President, Head Of Finance Natasha Rathee is SVP, Head of Finance at BlueRock Therapeutics where she is responsible for the Financial Planning and Analysis, Accounting and Financial Operations team playing a key role in the strategic and financial steering of the organization. Prior to B … een Columbia Business School and London Business School. He completed a Harvard fellowship training in Pediatric Cardiology at Boston Children’s Hospital. Read More Natasha Rathee Senior Vice President, Head Of Finance Natasha Rathee is SVP, Head of Finance at BlueRock Therapeutics where she is responsible for the Financial Planning and Analysis, Accounting and Financial Operations team playing a key role in the strategic and financial steering of the organization. Prior to B
FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate | Fujifilm [Mexico] This website uses cookies. By using the site you are agreeing to our Privacy Policy. Mexico Digital Cameras instax™ Films and QuickSnap™ Photo Printing Binoculars Healthcare IT MRI and CT X-ray Iｍaging Devices Mammography Endoscopy Ultrasound Systems In Vitro Diagnostics Veterinary Diagnostics Inkjet Solutions Graphic Arts & Printing Photofinishing Products Optical Devices Cine & Broadcast Products Security Protections Manufacturing P … o develop a new generation of iPSC-derived cell therapies and we are pleased to grant this license as the next step towards moving the OpCT-001 product into the clinic for the treatment of human retinal diseases” said Tomoyuki Hasegawa, president and chief executive officer, of FUJIFILM Cellular Dynamics. “We continue to have a productive partnership with BlueRock Therapeutics and look forward to unlocking the full potential of iPSC technology to create best-in-class cell rep
BlueRock Therapeutics Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies BlueRock Therapeutics Teams BlueRock Therapeutics Save Saved HQ Cambridge Total Offices: 2 361 Total Employees Year Founded: 2016 View Website Overview Jobs 3 Offices Is This Your Company? Manage Jobs Jobs at BlueRock Therapeutics Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. Recently posted jo
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
BlueRock Therapeutics - Cell & Gene Meeting on the Mesa October 5-7 | Arizona Biltmore Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda A
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker P … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BioWorks 23: Pioneering Cell T... — Columbia University BioWorks — Apple Podcasts Поиск Главная Новое Топ-чарты Поиск 11 марта 2025 г. 37 мин. BioWorks 23: Pioneering Cell Therapy: A Conversation with Mark Tomishima of BlueRock Therapeutics Columbia University BioWorks Воспроизвести Join us for an insightful episode as we sit down with Mark Tomishima, Senior Vice President at BlueRock Therapeutics, to explore the latest advancements in regenerative medicine. Mark shares his experiences leading genome engineering and stem cell research, discusses key challenges in cell therapy development, and
#teambayer | BlueRock Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BlueRock Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies BlueRock Therapeutics BlueRock Therapeutics is a pioneering cell therapy company dedicated to transforming the treatment of degenerative diseases through innovative regenerative medicines. Founded in 2016 and now a wholly owned subsidiary of Bayer AG, it focuses on developing authentic cell therapies for neurological, ophthalmic, cardiovascular, and immunological diseases, leveraging its proprietary _CELL+GENE_ platform and advanced cell differentiation t
Contact Us - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Contact Us Locations Cambridge CORPORATE HEADQUARTERS 238 Main Street, 3rd Floo … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Eye on the Cure Podcast - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRock Therapeutics 5 Jun 2025 Share this post on LinkedIn Share … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Expert Perspectives on the Use of Subcutaneous Infusion Therapies in Parkinson’s Disease - European Medical Journal Therapy Area Allergy & Immunology Cardiology Dermatology Diabetes Flagship Journal Gastroenterology General Healthcare Hematology Hepatology Innovations Interventional Cardiology Microbiology & Infectious Diseases Nephrology Neurology Oncology Radiology Reproductive Health Respiratory Rheumatology Urology Podcasts Journals Webinars Congress Hub Toolkit Paediatric Growth Calculator DVT Risk Calculator Due Date Calculator Mean Arterial Pressure (MAP) Calculator BMI Calculat … H Careers Contact Us Media Pack Editorial Enquiries Contributors & Authors Submit a Paper Media Partners Pharma Partners EMJ Interactive EMJ GOLD CME search Join FREE This site is intended for healthcare professionals You must accept all conditions before being able to view the post Continue EUR USA EUR USA Therapy Area Allergy & Immunology Cardiology Dermatology Diabetes Flagship Journal Gastroenterology General Healthcare Hematology Hepatology Innovations Intervent … H Careers Contact Us Media Pack Editorial Enquiries Contributors & Authors Submit a Paper Media Partners Pharma Partners EMJ Interactive EMJ GOLD CME Join FREE Home Flagship Journal Expert Perspectives on the Use of Subcutaneous Infusion Therapies… Expert Perspectives on the Use of Subcutaneous Infusion Therapies in Parkinson’s Disease 17 Mar 2026 18 Mins Flagship Journal Neurology View All Articles Download PDF Author: Samantha Stanbury Interviewees: Rajesh Pahwa … sts from a PD Diary through his University; acknowledges a Center of Excellence grant from the Parkinson Foundation; has received research support from AbbVie, Amneal Pharmaceuticals, Biogen MA, BlueRock Therapeutics, Inc., Cerevance Beta, Inc., Cerevel Therapeutics, F. Hoffman La Roche Ltd, Genentech, Inc., Global Kinetics Corporation, Ipsen, Michael J Fox Foundation, Motric Bio, Inc., Neuron23, Sun Pharma Advanced Research Company, Ltd., Teva Branded Pharmaceuticals, TrueBi … mics, Praxis Precision Medicines, Scion Neurostim, Teva, and Vima Therapeutics; grant support from the HDSA; and has served on the speaking bureau for AbbVie, Amneal Pharmaceuticals, Biogen, Kyowa Kirin, Merz, Neurocrine Pharmaceuticals, Supernus, and Teva. Isaacson, Lees, and Magee have not declared any conflicts of interest. Acknowledgements: M
It's always a pleasure to talk about BlueRock Therapeutics, starting with our Leaps by Bayer investment and Bayer | Pharmaceuticals' arm's length acquisition model. Recently, I sat down with Seth… | Juergen Eckhardt LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update you
Instagram Instagram Log In Sign Up Close Never miss a post from togetherforsharon2 Sign up for Instagram to stay in the loop. Sign up Log in togetherforsharon2 • Follow More options togetherforsharon2 6w Q & A with Sharon’s Son, George Episode 269 Special Guest Seth Ettenberg, PhD, President and Chief Executive Officer BlueRock Therapeutics. Hope for Regenerative Medicine for Tracking Parkinson’s Disease. https://youtu.be/aEMTASpw404 TogetherForSharon® In memory of my mother, Sharon to voice awareness & hope for a Parkinson’s Disease cure. Load more comments No comments yet. Start the
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
The Future Of iPSCs With BlueRock Therapeutics CEO Seth Ettenberg Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader
The Cell and Gene Podcast: The Future Of iPSCs With BlueRock Therapeutics' CEO Seth Ettenberg - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Co … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Bayer to Acquire BlueRock Therapeutics for Up-to-$600M, with Cell Therapy Pipeline in Mind genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine
Forging the future of cell therapy: Bayer and BlueRock’s unique journey - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRock Therapeut … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview … er , a scientific co-founder of BlueRock Therapeutics and 2015 MacArthur Genius Award winner, and Viviane Tabar , neuro surgeon and founding investigator of BlueRock Therapeutics, to advance stem cell therapy programs that address various neurological diseases with high unmet need. Dr. Studer, a world leader in the field of developing neurons from stem cells has pioneered large scale production of dopamine neurons and his research has led to important breakthroughs that show … s for the overall approach is iPSC intellectual property (IP) invented by Nobel Prize winner Dr. Shinya Yamanaka of Kyoto University and licensed from iPS Academia Japan Inc., which manages iPSC IP. This foundational IP will allow the company to create iPSCs, which will be an important cell source. "We have closely tracked the field of regenerative medicine for the past five years and believe the time is right to invest in stem cell therapies given recent breakthroughs in cel … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Just One Question Podcast: S3 E6 - Biotech expert Seth and Nick discuss revolutionary regenerative medicine treatments - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Priva … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
What A Week In CGT Approvals And Advancements Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Clinical Supply Lea
Instagram Instagram Log In Sign Up Close Never miss a post from executiveplatforms Sign up for Instagram to stay in the loop. Sign up Log in executiveplatforms • Follow Boston Marriott Copley Place More options executiveplatforms 162w It’s Day 2 at #PMWS23 ! Swipe to see all of the sessions you can look forward to today! #PMWS #PharmaNews #Pharmaceutical #Pharma #PharmaManufacturing #PharmaIndustry 🎤 Speakers featured: Karin Shanahan from Bristol-Myers Squibb Carlo de Notaristefani from Operation Warp Speed Jens Vogel from Bayer Pharmaceuticals Joanne Beck from Aerium Therapeutics Tim Moore f
Bayer BlueRock's Parkinson's Trial On Course For Phase 2 Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Clinical
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a Blu … g gene circuit company, today announced a collaboration and option agreement to apply Senti Bio’s gene circuit technology to the development of BlueRock’s next-generation engineered cell therapies for a potentially broad array of therapeutic areas, including but not limited to neurology, cardiology and immunology within the field of regenerative medicine. Under the terms of the agreement, Senti Bio will be responsible for designing, building and testing cell state- and diseas … y and immunology indications, as well as others. BlueRock Therapeutics plans to apply Senti Bio’s Smart Sensor and Regulator Dial gene circuit technology platform towards the goal of developing highly sophisticated engineered cell therapies. About Smart Sensors and Regulator Dials Smart Sensors are gene circuits designed to precisely detect cell type or disease environments, and thus distinguish between the “disease state” and “healthy state.” For example, Smart Sensors can b … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
The Science - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Turning What if? into Here’s how Science at BlueRock What if Instead of just t … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Become a BlueRocker - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Let’s redefine what’s possible in patient care Become a BlueRocker Blu … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Making a stop at BlueRock Therapeutics in Boston is always a special moment for me. The acquisition of this wonderful company was the first deal Bayer | Pharmaceuticals did since I joined in late… | Stefan Oelrich LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
BlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell Lines - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker P … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics | Portfolio | Versant Ventures Home Discovery Engines Team Portfolio Offices News ← View Portfolio BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. Company Name BlueRock Therapeutics Company Website http://bluerocktx.com/ Investment Stage Acquired by Bayer for up to $1B in total value in August 2019 Connected News Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Th
Science 2 - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Blaire Clause 11 Dec 2023 Share this post on LinkedIn Share this post on Twitter … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRo … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Platform - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions New discoveries shatter old beliefs We are working to push the boundaries of rege … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics Appoints Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BlueRock Therapeutics Appoints Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer November 26, 2018 | 3 min read Twitter LinkedIn Facebook Email Print BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative me … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Home - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Your browser does not support the video tag. Pause Background Video Your browser does … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align Summit Pa
BlueRock Therapeutics Job Openings & Careers | Justia Legal Jobs Post a Job Job Openings Post a Job AI Career Tools Legal Career Coach Cover Letter Generator Resume Review Interview Preparation Career Resources Newsletter Help Center in Find Jobs Justia Legal Jobs BlueRock Therapeutics BlueRock Therapeutics bluerocktx.com Click here to start a new search! AI Career Tools Turbocharge your job search with Justia's free AI career tools. Get personalized career guidance, tips for improving your resume, and more! AI Legal Career Coach Have chats and receive tips from Justia’s career coach chatbot!
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy | Dan Kim LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn
BlueRock Therapeutics Boston Jobs + Careers | Built In Boston Boston Global Tech Hub BuiltIn.com is the global destination for tech professionals. builtin.com Popular Tech Hubs United States Austin Boston Chicago Colorado Los Angeles New York City Seattle San Francisco Australia Sydney Melbourne Canada Calgary Montreal Ottawa Quebec Toronto Vancouver India Bengaluru Chennai Delhi Hyderabad Kolkata Mumbai Pune Ireland Dublin Singapore Singapore United Kingdom London Cambridge Manchester Birmingham Bristol Companies Jobs Articles Can't find your company? Create a company profile. View All J
BlueRock Therapeutics Announces Appointment of its CEO and President to The Alliance for Regenerative Medicine 2018 Executive Committee and Board of Directors - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science C … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics Location type All On-site Hybrid Remote Location All Cambridge, Massachusetts New York City, New York Toronto, Ontario Team All Development Clinical Development Clinical Trial Execution Translational Medicine Research Stem Cell Biology Technical Operations Device Development GMP Quality Operations Process Development Work type All Full-time Development Clinical Development Apply Associate Director, Clinical Operations Study Lead (COSL) Hybrid — Full-time Cambridge, Massachusetts Apply Senior Medical Director, Clinical Safety Hybrid — Full-time Cambridge, Massachusetts Cli … cal Safety Hybrid — Full-time Cambridge, Massachusetts Clinical Trial Execution Apply Senior Manager Systems and Metrics, Clinical Operations Hybrid — Full-time Cambridge, Massachusetts Translational Medicine Apply Director, Translational Medicine, Imaging Hybrid — Full-time Cambridge, Massachusetts Research Stem Cell Biology Apply Senior Research Associate, Research On-site — Full-time New York City, New York Technical Operations Device Development Apply Director, Device Dev … , Device Development Hybrid — Full-time Toronto, Ontario GMP Quality Operations Apply Senior Manager, External Manufacturing & Development Services Hybrid — Full-time Cambridge, Massachusetts Process Development Apply Principal Research Associate, Process Development On-site — Full-time New York City, New York BlueRock Therapeutics Home Page We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resu … responses and identifying potential inconsistencies or verification signals in application materials based on available information. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us. Jobs powered by
BlueRock Therapeutics | MaRS Discovery District Job Board Startups Membership MaRS Connect Directory Partners Our fund Our hubs Innovation Hubs About Innovation Hubs MaRS Centre MaRS Waterfront Our Tenants Workspaces Lab Spaces Office Spaces Coworking at MaRS Waterfront MaRS Incubator Events Upcoming Events Event Spaces Work in tech Our stories Sign in Startups Membership MaRS Connect Directory Partners Our fund Our hubs Innovation Hubs About Innovation Hubs MaRS Centre MaRS Waterfront Our Tenants Workspaces Lab Spaces Office Spaces Coworking at MaRS Waterfront MaRS Incubator Events Upcoming E
Story BlueRock ABOUT Who We Are Our Team The Toronto Advantage Our Strategy Our Success Stories Policies Awards Careers Accelerator Fund For Researchers UHN Community Academic Partners For Industry Our Philosophy UHN Opportunity Collaborating With Researchers Resources Express Agreements For Investors New Ventures Our Companies Our New Venture Model Resources News & Events Contact < Back to Success Stories BlueRock Therapeutics – Rocking the World of Cellular Medicines From its record-breaking financing to full acquisition, BlueRock Therapeutics continues a strong partnership with UHN i … foundational platform licensing, and to set up a a Master Research Agreement to fund future work at UHN. This funding helped to build and support R&D facilities in Toronto, New York and Boston – bringing together academic and industry partners with a goal to enable the volume manufacture of suitable, specialized stem cells to treat patients around the world. Today, BlueRock's proprietary cell + gene platform addresses various diseases including cardiovascular disea
BlueRock Therapeutics Announces Key Members of Executive Team - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRock Therapeutics 27 Jun … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Company: BlueRock Therapeutics Logo mobilemenu close CMN Live Home Clinical Trials CMN DB 2.0 CRISPRMED CRISPRMED24 CRISPRMED25 CRISPRMED26 WDC CRISPRMED26 Contest CRISPRMED26 Conference Kit CRISPRMED27 CRISPRMED Website Policies EGMEDC CMN Intelligence Webinars CMN Webinars On-demand - All CMN Webinar - Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines CMN Webinar - Taking the Guesswork Out of Drug Development: CRISPR-Select Validates Drug Targets and Drug Responders Early and Conclusively CMN Webinar - Clinical-Grade gRNA for Genomic Medicines: Making Se … rapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for... CARBON Newsletter (19 June 2026) - Your Latest... Carbon Jun. 19, 2026 Some of the best links we picked up around the internet Scaling CRISPR-based gene editing through advanced... Sponsored content Jun. 18, 2026 Addressing manufacturing bottlenecks in the transition to clinical scale. Clinical: Single CRISPR Infusion Curbs Hereditar
Instagram Instagram Log In Sign Up Close Never miss a post from nextgreatbigideas Sign up for Instagram to stay in the loop. Sign up Log in nextgreatbigideas and ngbipodcasts More options nextgreatbigideas 9w Based in Toronto, Ontario, BlueRock Therapeutics is a cell and gene therapy company working at the forefront of regenerative medicine. Their lead program is focused on developing a dopaminergic neuron therapy for Parkinson's disease, with phase three trials on the horizon and an ophthalmology program not far behind. In this episode, host Jim Wilson speaks with Senior Director of GMP
Bemdaneprocel - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 10 Jun 2026 Bemdaneprocel Last update 10 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Stem cell therapy Synonyms BRT DA01, BRT-DA01, DA-01 + [2] Target - Action - Mechanism Cell replacements Therapeutic Areas Nervous System Diseases Endocrinology and Metabolic Disease Active Indication Parkinson Disease Inactive Indication - Originator Organization BlueRock … for Parkinson's disease is massive. TFG-001 will be ready for a Clinical Trial Application (CTA) in 2027. TreeFrog Therapeutics is exploring co-development and commercialization of TFG-001. To discuss the program further, please attend poster session 3: Time / Date: Wednesday, May 27, 2026 –11:30AM – 1:30PM Location: Hall D-E (3 rd floor) Poster Board: P02.03 Abstract title: Advancing neural microtissues toward a clinically viable cell therapy for Parkinson’s disease About T … of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurospheres for Clinical Application. JPD 12, 871–884. ii Park, S. et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson’s disease. Cell Stem Cell 31, 25-38.e8. iii Piao, J. et al. Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell 28, 217-229.e7. iv Kirkeby, A. et all Prec
BlueRock Tx: Seth Ettenberg, CEO Biomarker Subscribe Sign in BlueRock Tx: Seth Ettenberg, CEO “I think that's how you do your best work…get in a room where you are constantly challenged.” Dylan Neel, MD PhD and Henry Klingenstein Nov 09, 2022 2 Share Hebe, daughter of Zeus, had many tasks on Mount Olympus. The majority were of the domestic variety—drawing baths, helping Hera into her chariot and waiting on Aphrodite. Yet, Ovid writes that she was cherished by Zeus, well ahead of her more famous siblings. How did she attain such stature? The reason is simple—regenerative medicine. Hebe (“ bloom
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease October 7, 2025 | 8 min read Twitter LinkedIn Facebook Email Print Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Pha … with baseline after 36 months. Two participants in the high dose cohort did not submit a 36-month PD Diary. Time spent in the “OFF” state showed a mean decrease of - 0.93 hours from baseline after 36 months. The participants in the low dose cohort showed a mean increase of 0.23 hours in the “Good ON” state time compared with baseline and a corresponding mean decrease of –1.15 hours in “OFF” state time. In the high dose cohort, the 36-month measurement of the effects of bemdan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search New … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases July 8, 2025 | 8 min read Twitter LinkedIn Facebook Email Print OpCT-001 is the first iPSC-derived investigational cell therapy to be … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale October 10, 2023 | 8 min read Twitter LinkedIn Facebook Email Print Bayer AG announced the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson’s disease clinical trial March 14, 2023 | 9 min read Twitter LinkedIn Facebook Email Print BlueRock Therapeutics LP today announced a collaboration with Rune La … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BlueRock Therapeutics Announces New Board Chair, New President and CEO - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BlueRock Therapeutics Announces New Board Chair, New President and CEO July 26, 2021 | 5 min read Twitter LinkedIn Facebook Email Print BlueRock Therapeutics announced today that Emile Nuwaysir , Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effect … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer March 3, 2020 | 2 min read Twitter LinkedIn Facebook Email Print BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team. CAMBRIDGE, Mass., March 03, 2 … ttenberg will oversee BlueRock’s research and discovery efforts, focused on the application and expansion of BlueRock’s cell+gene platform to the creation of engineered cellular medicines. “We are thrilled to have Seth join our team. He brings deep domain expertise in cell therapy and a track record of building and leading high-performance teams in both large pharma and start-up biotech companies,” said Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeuti … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
XML 73 R23.htm IDEA: XBRL DOCUMENT v3.25.1 Commitment and Contingencies 12 Months Ended Dec. 31, 2024 Commitments and Contingencies Disclosure [Abstract]   Commitments and Contingencies Commitments and Contingencies In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which the Company is liable in future periods. On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates.
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sear … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies December 20, 2021 | 23 min read Twitter LinkedIn Facebook Email Print Senti Biosciences, Inc. and Dynamics Special … armaceuticals; and Deep Nishar, Senior Managing Director of the Softbank Vision Fund. Dynamics’ Chief Scientific Advisor, Robert Langer, ScD, is the David H. Koch Institute Professor at MIT and a co-founder of over 30 companies, including Moderna (NASDAQ: MRNA). Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 with respec … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
What You Need to Know About BlueRock Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All Ne … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business What You Need to Know About BlueRock Therapeutics December 4, 2017 | 8 min read | Mark Terry Twitter LinkedIn Facebook Email Print What You Need to Know About BlueRock Therapeutics BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existe … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FUJIFILM Cellular Dynamics And Opsis Therapeutics Announce License With BlueRock Therapeutics For iPSC-Derived Cell Therapy Candidate Get more pharma outsourcing insight with our FREE newsletter sign me up Log In or Subscribe Explore CDMO Outsourcing Outsourcing 101 Preparing to Outsource Selecting a CDMO Onboarding & Tech Transfer Managing CDMOs Find Suppliers Bioanalytical Services Biologic Drug Substance Biologic Drug Product Cell & Gene Clinical Supply Fill/Finish Small Molecule API Small Molecule Drug Product Watch Now STREAM Video Channel Outsourced Pharma Capabilities Update Out … o develop a new generation of iPSC-derived cell therapies and we are pleased to grant this license as the next step towards moving the OpCT-001 product into the clinic for the treatment of primary photoreceptor diseases,” said Tomoyuki Hasegawa, president and chief executive officer, of FUJIFILM Cellular Dynamics. “We continue to have a productive partnership with BlueRock Therapeutics and look forward to unlocking the full potential of iPSC technology to create b
BlueRock Therapeutics and bit.bio announce collaboration Search Cancel Products Products How it works > Explore catalogue > Explore protocols > Explore by cell type Human liver cells ioHepatocytes Human muscle cells ioSkeletal Myocytes Human neuronal cells ioGABAergic Neurons ioGlutamatergic Neurons ioMotor Neurons ioSensory Neurons Human glial cells ioAstrocytes ioMicroglia ioOPC- & ioOligodendrocyte-like cells Custom ioCells Development Explore by disease area ALS and FTD Alzheimer's disease Duchenne Muscular Dystrophy Huntington's disease Parkinson's and Gaucher disease Custom … disease Parkinson's and Gaucher disease Custom ioDisease Model Cells Explore by application or assay CRISPR knockout, activation and interference CRISPR Screening Electrophysiology: MEA assays and more Immunocytochemistry (ICC) New Approach Methodologies (NAMs) Services Services CRISPR Screening Custom ioCells Development Custom ioDisease Model Cells Platform Resources Resources Product information Brochures User manuals General resources Application & technical notes Blo … g & storage FAQs Academic hub Data exchange program New lab discount Travel grant About us About us Our company About us Leadership Boards Sustainability News Events Careers Working at bit.bio Open roles How we hire Work with us Partners CONTACT US Search Home About us News BlueRock Therapeutics and bit.bio announce collaboration 03.08.2023 | Published by bit.bio BlueRock Therapeutics and bit.bio announce collaboration BlueRock Therapeutics and bit.bio announce collaborat … rapeutics Product Information Brochures Protocol library User manuals Resources Application notes Case studies Infographic Posters Publications Talks Videos Video tutorials Webinars About About us Sustainability Partners Careers Open Roles Working at bit.bio News and Events News Events Contact Contact us Tel: +44 (0) 1223 787297 Email: [email protected] Follow us LinkedIn X Policies Cookie notice Diversity & inclusion E-commerce terms & conditions of sale Limited use licen
BlueRock's Cell Therapy Receives FDA Orphan Drug Designation | BlueRock Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … DAQ: BRTX) has received FDA feedback on a potential expedited Biologics License Application (BLA) pathway for the Fast-Track-Designated BRTX-100 program for chronic lumbar disc disease (cLDD), following a company-requested Type B meeting. https://lnkd.in/gtfbHzMY BioRestorative reports positive FDA Type B meeting outcome; FDA endorses Phase 3 study design - BioTuesdays https://biotuesdays.com 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Isaa … pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for [...] Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA https://fgbn.org Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Boston Cambridge Biotech Networks 7,846 followers 5mo Report this post BCBN Feed: Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior … od and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for... ... [...] Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Isaac TW 4mo Report this post 📣 Arrowhead Pharmaceuticals Begins Clinical Study for New RNAi Therapeutic 💊 ARO-DIMER-PA 🏢 Arrowhead Pharmac
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Relea … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Instagram Instagram Log In Sign Up Close Never miss a post from bchstemcell Sign up for Instagram to stay in the loop. Sign up Log in bchstemcell • Follow More options bchstemcell 63w Join us next Tuesday, April 15th for the Stem Cell Program's 20th Anniversary Symposium. Seth Ettenberg, President and CEO of BlueRock Therapeutics discusses the impact the Stem Cell Program and other associations have had on the stem cell field and the contributions that will continue to be made in the years to come. Dr. Ettenberg will be speaking in the "Translating Therapies Into Practice" secti
Bayer AG to Acquire BlueRock Therapeutics at $1 Billion Value | News & Events | Goodwin Skip to main content Goodwin Expertise People Careers Legal Paralegal Science Advisor Global Operations Team Insights & Resources About Us Our Story The Goodwin Way Opportunity, Inclusion, and Belonging Pro Bono Firm Leadership Locations News & Events Alumni Press Release August 8, 2019 Bayer AG to Acquire BlueRock Therapeutics at $1 Billion Value Professionals Robert E. Puopolo Noelle C. Dubiansky Sarah A. Solomon Daniel S. Karelitz Jennifer Merrigan Fay Paul S. Jin Sarah M. Bock Erini R. Svoko … va Launches AHZANTIVE® Aflibercept Biosimilar in Europe Alert June 22, 2026 SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies Alert June 18, 2026 Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates Insight June 18, 2026 Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations Big Molecule Watch June 16,
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmolo … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics - Moving Day Parkinson's Moving Day logo Donate Give a gift to a participant or event Register Sign up to participate in a Moving Day event About About Moving Day About Parkinson’s Foundation About Parkinson’s Disease Why We Move Fundraising Tools Volunteer National Leaderboard FAQ/Website Help Log In --> Log in to your Moving Day participant center National Partner – BlueRock Therapeutics BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell thera
BlueRock Therapeutics - ARVO 2025 Skip to Main Content BlueRock Therapeutics Event starts in: 00 DAYS 00 HRS 00 MINS 00 SECS May 4 to May 7, 2025 Salt Palace Convention Center Salt Lake City, UT DASHBOARD EXHIBITOR DIRECTORY Login Create Account BlueRock Therapeutics Booth #1712, MS4 About About Contact About Contact Name BlueRock Therapeutics What We Do BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. BlueRock is harnessing the power of cell th
BlueRock Therapeutics Reports Positive 36-Month Phase I Results | BAYRY Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypt … with baseline after 36 months. Two participants in the high dose cohort did not submit a 36-month PD Diary. Time spent in the “OFF” state showed a mean decrease of - 0.93 hours from baseline after 36 months. The participants in the low dose cohort showed a mean increase of 0.23 hours in the “Good ON” state time compared with baseline and a corresponding mean decrease of –1.15 hours in “OFF” state time. In the high dose cohort, the 36-month measurement of the effects of bemdan
Instagram Instagram Log In Sign Up Close Never miss a post from insta_tomo360 Sign up for Instagram to stay in the loop. Sign up Log in insta_tomo360 • Follow More options insta_tomo360 Edited • 46w What a night! A few days ago, our Chief Connector, Susu Wong joined BlueRock Therapeutics’ first @outbio.bos event in July, and the energy was electric. ⚡️ Thoughtful conversations, genuine connections, and an inspiring showcase of our LGBTQ+ biotech community. Here’s to many more! #outbio #LGBTQ #biotech #LGBTQCommunity Load more comments No comments yet. Start the conversation. Like 8 Comment Sha
Job Listings - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Job Listings Follow BlueRock Therapeutics on Linkedin Privacy Policy Cookie S … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become … and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD). This is the first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease. Under the IND, BlueRock and MSK will execute a Ph1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with PD … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become … co-founder of BlueRock Therapeutics, and recipient of the 2015 MacArthur Genius Award and the 2017 Ogawa-Yamanaka Stem Cell Prize; and Viviane Tabar, M.D., newly announced Chair of the Department of Neurosurgery at MSK and founding investigator of BlueRock Therapeutics, who was recently elected into the National Academy of Medicine. Dr. Studer is a global leader in the field of developing neural cells from stem cells and his expertise will be leveraged by BlueRock in the deve … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
BlueRock Therapeutics Establishes Key Partnerships with Leading Experts in Autoimmune Disease - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditi … nd Pediatric Hematology/Oncology/Bone Marrow Transplantation after completing a residency and fellowship, respectively at the University of Minnesota. Dr. Courtney Crane is a Principal Investigator at the Ben Towne Center for Childhood Cancer Research at Seattle Children’s and Assistant Professor at the University of Washington School of Medicine. Dr. Crane’s lab specifically focuses on understanding how cancer cells disarm immune cells, with the aim of developing approaches … ane received her Ph.D. from the University of Virginia and completed a research fellowship in the department of neurosurgery at the University of California, San Francisco. About BlueRock Therapeutics BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock’s Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock’s … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Media Kit - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Media Kit Scroll to top of page Close video player News Media Library Video Feat … and updates Email Consent By signing up you agree to BlueRock's privacy policy Submit Follow BlueRock Therapeutics on Linkedin Privacy Policy Cookie Settings Terms & Conditions Accessibility About BlueRock Mission & Values Leadership News Media Kit Contact Us Our Science Cell Therapy Pipeline Programs Clinical Trials Become a BlueRocker © 2026 BlueRock Therapeutics LP You are now leaving the BlueRock Therapeutics website. This link will take you to a third-part … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clin … , Milky Way, Charles River Laboratories, National Resilience, Tencent, Verition Fund and Puhua Capital. bit.bio’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency. Our discovery platform extends this approach to any desir … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Life at BlueRock: Patty Sachamitr - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions BlueRock Therapeutics 20 Jun 2023 Share this post on Lin … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Instagram Instagram Log In Sign Up Close Never miss a post from neparkinsonsride Sign up for Instagram to stay in the loop. Sign up Log in neparkinsonsride • Follow More options neparkinsonsride 118w BlueRock is back as the 2024 Title Sponsor! BlueRock Therapeutics, a clinical-stage cell therapy company and subsidiary of Bayer AG, is dedicated to revolutionizing disease treatment through cell therapy. BlueRock’s lead clinical program, bemdaneprocel (BRT-DA01), will begin enrolling a Phase II clinical trial for Parkinson's disease in 2024, demonstrating their commitment to discovering a br
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mu … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Programs - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Transformative cell therapy programs We are currently pursuing the creation of ne … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel
Leadership - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions Leadership Select from one of the following Leadership groups to display … een Columbia Business School and London Business School. He completed a Harvard fellowship training in Pediatric Cardiology at Boston Children’s Hospital. Read more about Craig Beasley Craig Beasley Chief Technology Officer × Close dialog Craig Beasley Chief Technology Officer Craig Beasley is the Chief Technical Officer at BlueRock Therapeutics. Prior to joining BlueRock, Craig was the Vice President, Cell Therapy Supply Chain at BMS, where he oversaw supply chain for … his research dissertation in molecular neurovirology. He completed a neurology residency at Johns Hopkins School of Medicine in Baltimore Maryland, and served on the faculty Johns Hopkins for 10 years. In 2017, Doug founded and joined Generation Bio-a biotech company focused on non-viral gene therapy- as the head of R&D/CSO and then the Chief Medical Officer. In 2023, Doug became a Venture Partner at Atlas Venture where he is working on creating new biotech startups. Rea … . He is currently leading a multidisciplinary consortium to pursue the clinical application of human stem cell-derived dopamine neurons for the treatment of Parkinson’s disease. Dr. Studer’s work has been recognized by numerous awards including the Boyer Young Investigator award, the Annemarie Opprecht Award and a MacArthur Fellowship. Read more about Michael Laflamme, M.D., Ph.D. Michael Laflamme, M.D., Ph.D. Senior Scientist, Toronto General Hospital Research Institute &tim … nd Pediatric Hematology/Oncology/Bone Marrow Transplantation after completing a residency and fellowship, respectively at the University of Minnesota. Read more about Viviane Tabar, M.D. Viviane Tabar, M.D. Chair, Department of Neurosurgery; Theresa Feng Chair in Neurosurgical Oncology × Close dialog Viviane Tabar, M.D. Chair, Department of
We are thrilled to announce BlueRock Therapeutics LP as the new Title Sponsor for the 2023 New England Parkinson's Ride! BlueRock Therapeutics, a clinical stage cell therapy company and subsidiary of Bayer AG, strives to transform the treatment of disease by harnessing the power of cell therapy. BlueRock’s lead clinical program, bemdaneprocel (BRT-DA01), is currently in Phase 1 clinical trials for Parkinson's disease, exemplifying their commitment to finding a breakthrough treatment for this condition. By joining forces with us at the New England Parkinson's Ride, we aim to driv
About - BlueRock Therapeutics LP Skip to content About Learn More About BlueRock Mission & Values Leadership News Media Kit Our Science The Science at BlueRock Cell Therapy Programs Neurology Ophthalmology Pipeline Clinical Trials Become a BlueRocker Cell Therapy 101 Cell Therapy 101 About Mission & Values Leadership News Learn About BlueRock Our Science Cell Therapy Programs Neurology Ophthalmology Pipeline Learn About the Science Clinical Trials Become a BlueRocker Privacy Policy Terms & Conditions The Science of Cell Therapy Exploring new frontiers in science and medicine to chang … ink will take you to a third-party website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website which are undertaken at your own risk. BlueRock does not control the content of external websites or links contained in them. BlueRock does not investigate, monitor or check the accuracy, appropriateness or completeness of the content of external websites. Proceed Cancel